Premium
Antitumor effects of a recombinant pseudotype baculovirus expressing Apoptin in vitro and in vivo
Author(s) -
Pan Yongfei,
Fang Liurong,
Fan Huiying,
Luo Rui,
Zhao Qian,
Chen Huanchun,
Xiao Shaobo
Publication year - 2010
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.24959
Subject(s) - in vivo , apoptosis , in vitro , genetic enhancement , recombinant dna , cancer research , virology , biology , viral vector , equine infectious anemia , gene delivery , vector (molecular biology) , virus , gene , biochemistry , genetics
Apoptin, a chicken anemia virus‐derived, p53‐independent, bcl‐2‐insenstive apoptotic protein with the ability to specifically induce apoptosis in tumor or transformed cells, is a promising tool for cancer gene therapy. In this study, pseudotype baculovirus, a recently developed alternative gene delivery system, was used as a vector to express Apoptin. The resultant recombinant baculovirus (BV‐Apoptin) efficiently expressed the Apoptin protein and induced apoptosis in HepG2 and H22 cells. Studies in vivo showed that intratumoral injection of BV‐Apoptin into a xenogeneic tumor (derived from H22 murine hepatoma cells in C57BL/6 mice) significantly suppressed tumor growth, and significantly prolonged the survival of tumor‐bearing mice compared to a control pseudotype baculovirus that expressed EGFP. Taken together, these results suggest that Apoptin, expressed from the pseudotype baculovirus vector, has the potential to become a therapeutic agent for the treatment of solid tumors.